Pharmaceutical major, Cipla is reportedly planning to acquire office space in central Mumbai. The deal is worth over Rs 270 crore and could be finalized in the next few days.
The proposed deal, which is about 1.30 lakh sq ft at Peninsula Business Park in Lower Parel, is expected to become the company’s new headquarter. Following which, the company’s existing 70-year-old headquarters at Bellasis Road, south Mumbai, would be converted into a training centre.
Cipla manufactures drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other health conditions. Its products are distributed in more than 180 countries worldwide. The Mumbai-based firm which enjoys the highest share in India's pharmaceuticals market is known for selling low-cost generic versions of anti-retroviral drugs used to fight HIV/AIDS.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1670.40 |
| Dr. Reddys Lab | 1235.00 |
| Cipla | 1232.60 |
| Zydus Lifesciences | 936.50 |
| Lupin | 2327.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: